Clinical Trial Update: Intratumoral Poly-ICLC Plus Low Dose Local Radiation in Low Grade Recurrent B and T Cell Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 trial assessing intratumoral Poly-ICLC with low-dose local radiation in low-grade recurrent B-cell and T-cell lymphomas; the study was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Lymphoma
• T-cell Lymphoma

Drugs mentioned

• Poly-ICLC (Hiltonol) (polyinosinic-polycytidylic acid stabilized with poly-L-lysine)

Snippet

Sponsor: Nevada Cancer Institute | Conditions: B Cell Lymphoma, T Cell Lymphoma | Phase 1 | Status: TERMINATED